Cancers Symposium, and the updates were full of hope for people with advanced prostate cancer. CURE highlights two studies ...

In this observational study, researchers aimed to assess real-world use of relugolix among prostate cancer patients.

In the real-world, Pluvicto™ showed 13.5 months median PFS in chemo-naïve patients with PSMA-positive mCRPC; Real‑world evidence showed Pluvicto achieved longer PFS when init ...

A new study using serial liquid biopsies to track how metastatic prostate cancer evolves under treatment pressure showed that ...

Erleada showed a 23% reduction in mortality compared to Xtandi in real-world settings, offering potential survival benefits for metastatic castration-sensitive prostate cancer patients. Real-world ...

A growing array of pharmaceutical options has investigators trying to figure out which drugs and drug combinations are the best to prescribe upfront—and to which patients. Over the past 14 years, ...

There are different ways to manage fatigue during prostate cancer treatment, including exercise, sleep, complementary ...

Flatiron Health, a leading healthtech company dedicated to improving cancer care and advancing research using real-world data, today announced their first Panoramic datasets in the UK and Germany for ...